High Dose Testosterone Treatment for People with Metastatic Prostate Cancer and an ATM, CDK12 or CHEK2 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/294/high-dose-testosterone-treatment-for-people-with-metastatic-prostate-cancer-and-an-atm-cdk12-or-chek2mutation
Clinicaltrials.gov identifier:
NCT05011383 (https://clinicaltrials.gov/show/NCT05011383)
Treatment
People who have metastatic castration-resistant prostate cancer with an ATM, CDK12, or CHEK2 mutation
Study Contact Information:
For additional information, please contact:
Principal Investigator: Robert B Montgomery, MD, (206) 277-6878, Email: [email protected] or
Elahe Mostaghel, MD, (206) 762-1010, Email: [email protected]
About the Study
This study will examine how well an increased dose of testosterone treatment works for people with metastatic castration-resistant prostate cancer (mCRPC) with an ATM, CDK12, or CHEK2 genetic mutation. Participants will continue to receive the medication as long as their cancer doesn’t get worse and they do not experience severe side effects.
Side effects and vital signs will be recorded to examine the safety and tolerability of the therapy. Participants will receive a bone scan, CT scan, and blood test to determine if the cancer is advancing.
What the Study Involves
Participants will get a shot with an elevated dose of testosterone once a month as long as their cancer doesn’t get worse and they do not experience severe side effects. They will receive a bone scan, CT scan, and PSA regularly to measure the effectiveness of the medication.
Study Sites
Colorado
Aurora
Rocky Mountain Regional VA Medical Center
Contact: Daniel Bowles, MD 720-723-6498 [email protected]
Connecticut
West Haven
VA Connecticut Healthcare System West Haven Campus
Contact: Herta Chao, MD 203-584-0902 [email protected]
Florida
Gainsville
North Florida/South Georgia Veterans Health System
Contact: Jess D Delaune, MD 352-988-7504 [email protected]
Orlando
Orlando VA Medical Center
Contact: Priya K Gopalan, MD 407-631-2389 [email protected]
Georgia
Decatur
Atlanta VA Medical and Rehab Center
Contact: Maria Ribeiro, MD 404-728-7680 [email protected]
Kentucky
Louisville
Robley Rex VA Medical Center
Contact: Fred Hendler, MD 502- 28-3515
Missouri
Kansas City
Kansas City VA Medical Center
Contact: Linda Verkruyse, MD 817-681-7115 [email protected]
Saint Louis
St. Louis VA Medical Center John Cochran Division
Contact: Eric Knoche, MD 314-289-6305 [email protected]
North Carolina
Durham
Durham VA Medical Center
Contact: Rhonda Bitting, MD 919-286-0411 ext 17-5441 [email protected]
Salisbury
Salisbury W.G. (Bill) Hefner VA Medical Center
Contact: Michael Goodman, MD 704-638-9000 ext. 15038
Oregon
Portland
VA Portland Health Care System
Contact: Julie Graff, MD 503-220-8262 [email protected]
South Carolina
Charleston
Ralph H. Johnson VA Medical Center
Contact: Steven Savage, MD 843-792-4531 [email protected]
Tennessee
Memphis
Memphis VA Medical Center
Contact: Alva Weir, MD 901-523-8990 ext. 6853
Nashville
Tennessee Valley Healthcare System Nashville Campus
Contact: Sally York, MD 615-873-6979
Washington
Seattle
VA Puget Sound Health Care System Seattle Division
Contact: Robert B Montgomery, MD 206-277-6878 [email protected]
Lead Researcher
Robert B Montgomery, MD, (206) 277-6878, Email: [email protected]
This Study is Open To:
Male assigned at birth, aged 18 years and older, who meet the following criteria:
- Veterans who can receive care within the VA medical system.
- Diagnosed with metastatic, castration-resistant prostate cancer
- Ongoing treatment that lowers the levels of male hormones produced by the testicles, which includes medications like gonadotropin-releasing hormone (GnRH) analogues or antagonists, or surgical removal of the testicles (orchiectomy)
- Have a genetic mutation in ATM, CDK12, or CHEK2 gene
- Do not have severe symptoms related to your cancer
- Your prostate cancer has progressed after using one of the newer hormone therapies for prostate cancer, such as abiraterone, enzalutamide, apalutamide, darolutamide, etc.
This Study is Not Open To:
People under the age of 18 who:
- Are currently receiving active therapy
- Have small cell lung cancer
- Have cancer that spread to the brain or liver
- Have viral hepatitis or chronic liver disease
- Have significant heart disease
- Have pain related to their cancer and are using opioids, such as oxycodone, hydrocodone (Vicodin), morphine, methadone or fentanyl
- Require a catheter to urinate
- Have dementia or a mental disorder that will limit your ability to participate in the study
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.